Intuitive Surgical (NASDAQ:ISRG) Price Target Raised to $675.00

Intuitive Surgical (NASDAQ:ISRG) had its price objective hoisted by analysts at JPMorgan Chase & Co. from $575.00 to $675.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has an “overweight” rating on the medical equipment provider’s stock. JPMorgan Chase & Co.‘s target price would indicate a potential upside of 10.90% from the stock’s previous close.

Several other research analysts have also weighed in on the company. Mizuho lifted their target price on Intuitive Surgical from $440.00 to $500.00 in a report on Thursday, October 17th. Stifel Nicolaus lifted their price objective on Intuitive Surgical from $525.00 to $610.00 and gave the company a “buy” rating in a report on Thursday, December 5th. The Goldman Sachs Group set a $604.00 target price on Intuitive Surgical in a research note on Friday, October 18th. Raymond James lifted their price target on shares of Intuitive Surgical from $500.00 to $540.00 and gave the company an “outperform” rating in a research note on Monday, October 14th. Finally, Evercore ISI reissued a “cautious” rating on shares of Intuitive Surgical in a research report on Friday, October 18th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $559.72.

Intuitive Surgical Stock Performance

Shares of NASDAQ:ISRG opened at $608.66 on Friday. The company has a 50 day moving average price of $544.61 and a two-hundred day moving average price of $502.64. The company has a market capitalization of $216.79 billion, a PE ratio of 97.86, a PEG ratio of 5.19 and a beta of 1.39. Intuitive Surgical has a 52 week low of $362.14 and a 52 week high of $616.00.

Insider Activity

In other Intuitive Surgical news, EVP Robert Desantis sold 188 shares of the company’s stock in a transaction that occurred on Tuesday, October 29th. The stock was sold at an average price of $506.52, for a total value of $95,225.76. Following the sale, the executive vice president now owns 5,506 shares in the company, valued at $2,788,899.12. This represents a 3.30 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Jamie Samath sold 269 shares of the stock in a transaction on Monday, November 11th. The shares were sold at an average price of $539.89, for a total value of $145,230.41. Following the completion of the sale, the insider now owns 8,757 shares in the company, valued at approximately $4,727,816.73. This trade represents a 2.98 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 42,475 shares of company stock valued at $22,070,807. 0.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On Intuitive Surgical

Hedge funds have recently bought and sold shares of the stock. Berbice Capital Management LLC acquired a new stake in Intuitive Surgical during the 4th quarter worth approximately $26,000. Godsey & Gibb Inc. boosted its position in shares of Intuitive Surgical by 140.0% in the third quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 35 shares during the period. MidAtlantic Capital Management Inc. acquired a new position in shares of Intuitive Surgical in the third quarter valued at about $33,000. Decker Retirement Planning Inc. bought a new position in Intuitive Surgical during the fourth quarter worth about $36,000. Finally, Capital Performance Advisors LLP acquired a new stake in Intuitive Surgical in the 3rd quarter worth about $38,000. 83.64% of the stock is currently owned by institutional investors and hedge funds.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.